510(k) Summary – AMPLICOR CT/NG test for Neisseria gonorrhoeae with Roche Scripts for AMPLICOR CT/NG Test Accessory

Introduction According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence

Submitter name, address, contact Roche Diagnostics
9115 Hague Rd
Indianapolis IN 46250
(317) 521-3723

Contact person: Theresa A Bush

Date prepared: Jan 17, 2007

Device Name Proprietary Name: AMPLICOR CT/NG test for Neisseria gonorrhoeae; Roche Scripts for use on the Tecan Genesis RSP 150 Workstation (Roche Scripts Accessory)

Common name: Neisseria gonorrhoeae test system; software accessory

Classification name: DNA reagents, Neisseria

Device Description The AMPLICOR CT/NG test for Neisseria gonorrhoeae is a qualitative in vitro test for the detection of N. gonorrhoeae DNA in urine from symptomatic or asymptomatic males, in endocervical swab specimens from symptomatic or asymptomatic females, and in urethral swab specimens from symptomatic males as evidence infection with N. gonorrhoeae. N. gonorrhoeae DNA is detected by Polymerase Chain Reaction (PCR) amplification of target DNA and by hybridization capture of amplified target using the AMPLICOR analyzer.

The Roche Scripts for AMPLICOR CT/NG Test accessory consists of a compact disc (CDs) containing scripts to direct the automated Tecan Genesis RSP 150 workstation to process swab samples or control material for analysis.

Continued on next page
**510(k) Summary, Continued**

**Intended use**
The AMPLICOR CT/NG test for *Neisseria gonorrhoeae* is a qualitative in vitro test for the detection of *N. gonorrhoeae* DNA in urine from symptomatic or asymptomatic males, in endocervical swab specimens from symptomatic or asymptomatic females, and in urethral swab specimens from symptomatic males as evidence infection with *N. gonorrhoeae*. *N. gonorrhoeae* DNA is detected by Polymerase Chain Reaction (PCR) amplification of target DNA and by hybridization capture of amplified target using the AMPLICOR analyzer.

The Roche Scripts for AMPLICOR CT/NG Test are intended to provide software scripts to direct the automated Tecan Genesis RSP 150 Workstation to process swab samples or control material for analysis using either of the following 510(k)-cleared assay test systems:
- AMPLICOR® CT/NG test for Chlamydia trachomatis
- AMPLICOR® CT/NG test for Neisseria gonorrhoeae

**Predicate Device**
We claim equivalence to the currently marketed AMPLICOR CT/NG test for *Neisseria gonorrhoeae* cleared under K974503.

**Comparison - similarities**
The table below shows the similarities between the AMPLICOR CT/NG test for *Neisseria gonorrhoeae* with optional Roche Scripts accessory and the predicate device:

<table>
<thead>
<tr>
<th>Feature</th>
<th>Predicate Device: K974503 AMPLICOR CT/NG test for <em>Neisseria gonorrhoeae</em></th>
<th>Current Device: AMPLICOR CT/NG test for <em>Neisseria gonorrhoeae</em> with optional Roche Scripts accessory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product features</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Intended use

The AMPLICOR CT/NG test for *Neisseria gonorrhoeae* is a qualitative in vitro test for the detection of *N. gonorrhoeae* DNA in urine from symptomatic or asymptomatic males, in endocervical swab specimens from symptomatic or asymptomatic females, and in urethral swab specimens from symptomatic males as evidence of infection with *N. gonorrhoeae*. *N. gonorrhoeae* DNA is detected by Polymerase Chain Reaction (PCR) amplification of target DNA and by hybridization capture of amplified target.

Same intended use for AMPLICOR CT/NG test.

Roche Scripts for AMPLICOR CT/NG Test: The Roche Scripts for AMPLICOR CT/NG Test are intended to provide software scripts to direct the automated Tecan Genesis RSP 150 Workstation to process swab samples or control material for analysis using either of the following 510(k)-cleared assay test systems:

- AMPLICOR® CT/NG test for *Chlamydia trachomatis*
- AMPLICOR® CT/NG test for *Neisseria gonorrhoeae*

### Test principle

DNA detection via PCR amplification of target DNA followed by hybridization capture of amplified target using the AMPLICOR Analyzer.

Same

### Controls provided

| Positive control: plasmid DNA from *N. gonorrhoeae* |
| Negative control: plasmid DNA from *C. trachomatis* |

Optional internal control: plasmid DNA with CT primer binding regions and a unique probe binding region.

Same

### Labeled test performance

| Analytical specificity |
| Negative results from 130 bacteria, 6 fungal, 1 protozoan and 11 viral strains. Some isolates from *N. cinerea* and *N. subflava* may give false positive results. |

Same
<table>
<thead>
<tr>
<th>Analytical sensitivity</th>
<th>5 IFU/test; equivalent to 100 IFU/mL for urine specimens and 400 IFU/mL for Culture Transport Medium (CTM) with swab specimen</th>
<th>Manual preparation: Same</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Automated preparation: 100 cfu/mL for CTM with swab specimen</td>
<td></td>
</tr>
<tr>
<td>Precision</td>
<td>100% correct results for panel of CTM specimens. Three (out of 30) negative test results for one urine panel member.</td>
<td>Manual preparation: Same</td>
</tr>
<tr>
<td></td>
<td>Automated preparation: 99.4% correct results for panels of CTM specimens</td>
<td></td>
</tr>
<tr>
<td>Clinical performance</td>
<td>Sensitivity vs. culture: • 95.9 % for females • 96.5 % for males Specificity vs. culture: • 98.7 % for females • 97.3 % for males (with internal control)</td>
<td>Manual preparation: Same</td>
</tr>
<tr>
<td></td>
<td>Automated preparation: 99.0% concordance with manual method</td>
<td></td>
</tr>
</tbody>
</table>

*Continued on next page*
The table below shows the differences between the AMPLICOR CT/NG test for *Neisseria gonorrhoeae* with optional Roche Scripts accessory and the predicate device:

<table>
<thead>
<tr>
<th>Feature</th>
<th>Predicate Device: K974503 AMPLICOR CT/NG test for <em>Neisseria gonorrhoeae</em></th>
<th>Current Device: AMPLICOR CT/NG test for <em>Neisseria gonorrhoeae</em> with optional Roche Scripts accessory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimen and control preparation options</td>
<td>Manual</td>
<td>• Manual</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Automated preparation using the Roche Scripts to direct the Tecan Genesis RSP 150 Workstation.</td>
</tr>
<tr>
<td>Specimen types</td>
<td>Male urine specimens; endocervical and urethral swabs</td>
<td>Manual: same</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Automated preparation: endocervical and urethral swabs only (no urine samples)</td>
</tr>
</tbody>
</table>

**Performance evaluation**

The Roche Scripts were developed and evaluated according to FDA Guidance documents.

The AMPLICOR CT/NG test for *Neisseria gonorrhoeae* with Roche Scripts accessory was evaluated for analytical performance characteristics including analytical sensitivity, cross-contamination, precision, and non-clinical specificity. Results were equivalent to those obtained with manual specimen preparation.

A clinical evaluation was performed where the results obtained using the AMPLICOR CT/NG test for *Neisseria gonorrhoeae* with automated specimen preparation using the Roche Scripts to direct the Tecan Genesis RSP 150 workstation were compared to results obtained with the manual specimen preparation method. Results were equivalent to those obtained with manual specimen preparation.
Re: k070172  
Trade/Device Name: AMPLICOR™ CT/NG Test for Neisseria gonorrhoeae; Roche Scripts for AMPLICOR CT/NG Test (Roche Scripts Accessory)  
Regulation Number: 21 CFR 866.3390  
Regulation Name: Neisseria species, Direct Serological Test Reagents  
Regulatory Class: Class II  
Product Code: LSL  
Dated: January 17, 2007  
Received: January 18, 2007

Dear Dr. Bush:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmmain.html.

Sincerely yours,

Sally A. Hojvat, M.Sc., Ph.D.
Director
Division of Microbiology Devices
Office of In Vitro Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health

Enclosure
Indications for Use

510(k) Number (if known): k070172

Device Name: AMPLICOR CT/NG test for Neisseria gonorrhoeae

Indications For Use:

The AMPLICOR CT/NG test for Neisseria gonorrhoeae is a qualitative in vitro test for the detection of N. gonorrhoeae DNA in urine from symptomatic or asymptomatic males, in endocervical swab specimens from symptomatic or asymptomatic females, and in urethral swab specimens from symptomatic males as evidence of infection with N. gonorrhoeae. N. gonorrhoeae DNA is detected by Polymerase Chain Reaction (PCR) amplification of target DNA and by hybridization capture of amplified target.

Sample and control preparation can either be accomplished manually or automated using the optional Roche Scripts for AMPLICOR CT/NG Test Accessory to direct the Tecan Genesis RSP 150 Workstation. Urine specimens are not indicated for use with the automated sample preparation option.
Indications for Use

510(k) Number (if known): 5070172

Device Name: Roche Scripts for AMPLICOR CT/NG Test Accessory

Indications For Use:

Roche Scripts for AMPLICOR CT/NG Test: The Roche Scripts for AMPLICOR CT/NG Test are intended to provide software scripts to direct the automated Tecan Genesis RSP 150 Workstation to process swab samples or control material for analysis using either of the following 510(k)-cleared assay test systems:
- AMPLICOR ® CT/NG test for Chlamydia trachomatis
- AMPLICOR ® CT/NG test for Neisseria gonorrhoeae

Prescription Use XXXX AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)